With our highly complementary and unequalled product portfolio following the combination, Pfizer China continues to be in a strong leading position to provide innovative solutions in the following categories: cardiovascular, endocrinology, neuroscience, arthritis and inflammation, infectious diseases, urology, ophthalmology and oncology.

Pfizer offers 40 innovative products in China, 8 of which global annual sales are greather than US$1 billion.